TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. has announced the appointment of Singer Capital Markets as its joint corporate broker, effective immediately. This strategic move is expected to enhance Novacyt’s market presence and strengthen its financial advisory team, working alongside SP Angel, the company’s existing joint corporate broker. The appointment reflects Novacyt’s commitment to bolstering its corporate governance and investor relations, potentially impacting its operations and industry positioning positively.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver seamless end-to-end solutions across sectors including human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, offering products and services in areas such as reproductive health, precision medicine, infectious diseases, DNA sample preparation, and qPCR assays. Headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada, Novacyt is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.